☆ 4.7 Article

Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation

JOURNAL OF CLINICAL ONCOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Molecular Classification of Appendiceal Adenocarcinoma

Michael B. Foote et al.

Summary: Appendiceal adenocarcinomas can be classified into three molecular subtypes: a clinically indolent RAS-mut/GNAS-wt/TP53-wt subtype, a chemotherapy-resistant GNAS-mut subtype, and an aggressive, highly aneuploid TP53-mut subtype. Each subtype exhibits conserved clinical behavior irrespective of histopathology.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C

Rona Yaeger et al.

Summary: In this study, the researchers investigated the clinical efficacy of adagrasib in combination with cetuximab for heavily pretreated patients with metastatic colorectal cancer harboring mutant KRAS G12C. The results showed that the overall response rate was 19% in the adagrasib monotherapy group, with a median progression-free survival of 5.6 months, and 46% in the combination therapy group, with a median progression-free survival of 6.9 months. Both groups experienced reversible adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Article Medicine, General & Internal

Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial

Brandon M. Huffman et al.

Summary: In this multicenter, randomized phase II clinical trial, NPC-1C did not enhance the efficacy of gemcitabine/nab-paclitaxel in advanced PDAC patients, providing benchmark data for future trials investigating second-line treatment of PDAC.

JAMA NETWORK OPEN (2023)

Add to Collection

Meeting Abstract Oncology

KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation

Tanios S. Bekaii-Saab et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)

Sai-Hong Ignatius Ou et al.

Summary: This study reported the results of a clinical trial using adagrasib to treat non-small-cell lung cancer, colorectal cancer, and other solid tumors with the KRAS(G12C) mutation. The recommended phase II dose was identified as 600 mg twice a day, and it demonstrated good tolerability and antitumor activity.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial

Marwan G. Fakih et al.

Summary: Sotorasib, a specific inhibitor of KRAS(G12C) protein, showed modest anti-tumour activity and manageable safety in heavily pretreated patients with colorectal cancer in a phase 2 trial. The overall response rate of 9.7% did not reach the benchmark, but sotorasib is being evaluated in combination with other therapeutics to enhance potential activity and address potential resistance mechanisms.

LANCET ONCOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer

J. H. Strickler et al.

Summary: This study evaluated the safety and efficacy of sotorasib in patients with KRAS p.G12C-mutated pancreatic cancer who had previously received treatment. The results showed that sotorasib demonstrated anticancer activity and had an acceptable safety profile in these patients.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation

Pasi A. Jaenne et al.

Summary: Adagrasib demonstrated clinical efficacy without new safety signals in previously treated KRAS(G12C)-mutated NSCLC patients.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Review Medicine, Research & Experimental

Histology-Agnostic Drugs: A Paradigm Shift-A Narrative Review

Andre Mansinho et al.

Summary: Cancer diagnosis and therapeutics have traditionally relied on organ-based pathological classification, but with the advancement of precision medicine, targeted therapies based on specific genomic or molecular alterations have emerged. Cancer is now recognized as a heterogeneous disease with multiple targetable mutations, leading to the development of novel trial designs and histology-agnostic targeted therapeutic agents.

ADVANCES IN THERAPY (2022)

Add to Collection

Meeting Abstract Oncology

Phase Ia study to evaluate GDC-6036 monotherapy in patients with solid tumors with a KRAS G12C mutation

M. Patel et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers

Mohamed E. Salem et al.

Summary: This study provides a comprehensive analysis of KRAS(G12C) mutations in various cancers, revealing its prevalence in females, older patients, and association with smoking status. KRAS(G12C) tumors exhibit distinct comutation profiles and are associated with high tumor mutational burden status.

JCO PRECISION ONCOLOGY (2022)

Add to Collection

Letter Medicine, General & Internal

Distribution of KRASG12C Somatic Mutations across Race, Sex, and Cancer Type

Amin H. Nassar et al.

Summary: A survey of over 32,000 cancers in the GENIE registry found differences in distribution of KRAS(G12C) mutations in various cancer types and between men and women of different races. As agents capable of targeting specific mutant alleles like sotorasib become available, tumor mutation analysis is becoming increasingly important in treatment selection.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

Angela Lamarca et al.

Summary: This study found that second-line FOLFOX chemotherapy can significantly improve overall survival in patients with advanced biliary tract cancer after progression on cisplatin and gemcitabine, indicating it should be considered as standard-of-care chemotherapy.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Jill Hallin et al.

CANCER DISCOVERY (2020)

Add to Collection

Review Oncology

Current standards and future perspectives in adjuvant treatment for biliary tract cancers

Angela Lamarca et al.

CANCER TREATMENT REVIEWS (2020)

Add to Collection

Article Oncology

KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population

Marta Schirripa et al.

CLINICAL COLORECTAL CANCER (2020)

Add to Collection

Review Medicine, General & Internal

Targeting Krasg12c-mutant cancer with a mutation-specific inhibitor

J. G. Christensen et al.

JOURNAL OF INTERNAL MEDICINE (2020)

Add to Collection

Article Oncology

EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer

Vito Amodio et al.

CANCER DISCOVERY (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Targeting MutantKRASin Pancreatic Cancer: Futile or Promising?

Friederike Inga Nollmann et al.

BIOMEDICINES (2020)

Add to Collection

Review Biotechnology & Applied Microbiology

RAS-targeted therapies: is the undruggable drugged?

Amanda R. Moore et al.

NATURE REVIEWS DRUG DISCOVERY (2020)

Add to Collection

Article Medicine, General & Internal

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

David S. Hong et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Pharmacology & Pharmacy

Targeting the untargetable KRAS in cancer therapy

Pingyu Liu et al.

ACTA PHARMACEUTICA SINICA B (2019)

Add to Collection

Article Oncology

Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery

Marc Uemura et al.

BMC CANCER (2017)

Add to Collection

Editorial Material Medicine, General & Internal

被撤回的出版物: World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects (Retracted article. See vol. 135, pg. 2149, 2021)

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)

Add to Collection

Article Multidisciplinary Sciences

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Jonathan M. Ostrem et al.

NATURE (2013)

Add to Collection

Review Oncology

A Comprehensive Survey of Ras Mutations in Cancer

Ian A. Prior et al.

CANCER RESEARCH (2012)

Add to Collection

© Peeref 2019-2024. All rights reserved.